A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Inclusion Criteria:
Exclusion Criteria:
Suite 101, Texas 76132, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires 1205, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1179AAB, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C141AH, Argentina
Leipzg, Saxony 04109, Germany
Nikaia Piraeus, 184 54, Greece
S.Andrea Delle Fratte - S. Sisto (PG), Umbria 06132, Italy
Monterrey NL, Nuevo León 64718, Mexico
Hoenefoss, 3513, Norway
Callao, Lima Callao 2, Peru
Gyeonggido, 420-717, South Korea
Kangwondo, 220-701, South Korea
Alzira/Valencia, 46600, Spain
Badalona / Barcelona, 08917, Spain
Canet de Mar - Barcelona, 08360, Spain
Cangas Del Narcea/Asturias, 33800, Spain
Pozuelo de Alarcón/Madrid, 28223, Spain
Sagunto/Valencia, 46520, Spain
Sanlucar de Barrameda - Cádiz, 11540, Spain
Santa Coloma de Gramanet (Barcelona), 08923, Spain
Vigo-Pontevedra, 36312, Spain
Fife, KY14 7AW, United Kingdom
Fife, KY2 5A, United Kingdom
Sidcup, Kent, DA14 6, United Kingdom